STAT+: Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is especially modest. We hope to tend to the Pharmalot campus, take our short person for a dollop of ice cream, and promenade with the official mascot. And what about you? This is a fine time to enjoy the great outdoors, so perhaps a jaunt to the beach or a hike up a mountain is in order. You could engage in a little spring cleaning. Or simply catch up on your reading. Well, whatever you do, have a grand time, and be safe. Enjoy, and see you soon. …

A pharmaceutical turnaround artist has teamed up with a former Martin Shkreli acolyte in an effort to depose him, recruiting a few industry lifers with a new plan for the former Turing Pharmaceuticals, STAT reports. If they succeed, step one would be undoing the 4,000% price increase on the drug that transformed Shkreli from an anonymous entrepreneur into the reviled “pharma bro.” “I want to right the wrongs,” Jason Aryeh, a health care investor, told STAT. “I want to throw the bad guys out. There isn’t a bigger, badder guy than Martin Shkreli.”

Continue to STAT+ to read the full story…